Can we build an efficient response to the prescription drug abuse epidemic? Assessing the cost effectiveness of universal prevention in the PROSPER trial

Preventive Medicine

Volumn 62, Issue , 2014, Pages 71-77

  Max Crowley, D ^a   Jones, Damon E ^b   Coffman, Donna L ^b   Greenberg, Mark T ^b  

^a DUKE UNIVERSITY   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

Cost effectiveness; Nonmedical prescription drug use; Prevention economics; Substance abuse; Universal prevention

Indexed keywords

OPIATE; PRESCRIPTION DRUG;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG ABUSE; EPIDEMIC; EVIDENCE BASED PREVENTIVE INTERVENTION; FAMILY; FAMILY ASSESSMENT; GEOGRAPHY; GROUPS BY AGE; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPIATE ADDICTION; PREVALENCE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROPENSITY SCORE; RISK REDUCTION; RURAL POPULATION; SCHOOL; UNITED STATES; CHILD; CLINICAL TRIAL; COST BENEFIT ANALYSIS; EVIDENCE BASED PRACTICE; FAMILY THERAPY; FEMALE; FOLLOW UP; MALE; OPIOID-RELATED DISORDERS; OUTCOME ASSESSMENT; PROGRAM EVALUATION; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; STUDENT; SUBSTANCE-RELATED DISORDERS; TIME; TREATMENT OUTCOME;

ADOLESCENT; CHILD; COST-BENEFIT ANALYSIS; EVIDENCE-BASED PRACTICE; FAMILY; FAMILY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IOWA; MALE; OPIOID-RELATED DISORDERS; OUTCOME ASSESSMENT (HEALTH CARE); PENNSYLVANIA; PROGRAM EVALUATION; RURAL POPULATION; SCHOOLS; STUDENTS; SUBSTANCE-RELATED DISORDERS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84896893892     PISSN: 00917435     EISSN: 10960260     Source Type: Journal    
DOI: 10.1016/j.ypmed.2014.01.029     Document Type: Article

References (57)

1. Aos S., Lieb R., Mayfield J., Miller M., Pennucci A. Benefits and Costs of Prevention and Early Intervention Programs for Youth 2004.
2. Aos S., Lee S., Drake E.K., et al. Return on Investment: Evidence-based Options to Improve Statewide Outcomes 2011.
3. Birnbaum H.G., White A.G., Schiller M., Waldman T., Cleveland J.M., Roland C.L. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med. 2011, 12:657-667.
4. Briggs A.H., Wonderling D.E., Mooney C.Z. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ. 1997, 6:327-340.
5. Catalano J. Pain management and substance abuse: a national dilemma. Soc. Work Public Health 2009, 24:477-490.
6. Catalano R.F., White H.R., Fleming C.B., Haggerty K.P. Is nonmedical prescription opiate use a unique form of illicit drug use?. Addict. Behav. 2011, 36:79-86.
7. Centers for Disease Control and Prevention Prescription Painkiller Overdoses at Epidemic Levels 2011, CDC Press Release.
8. Coben J.H., Davis S.M., Furbee P.M., Sikora R.D., Tillotson R.D., Bossarte R.M. Hospitalizations for poisoning by prescription opioids, sedatives, and tranquilizers. Am. J. Prev. Med. 2010, 38:517-524.
9. Compton W.M., Volkow N.D. Abuse of prescription drugs and the risk of addiction. Drug Alcohol Depend. 2006, 83:S4-S7.
10. Connock M., Juarez-Garcia A., Jowett S., et al. Methadone and Buprenorphine for the Management of Opioid Dependence: A Systematic Review and Economic Evaluation 2007.
11. Crowley D.M., Jones D.E., Greenberg M.T., Feinberg M.E., Spoth R. Resource consumption of a diffusion model for prevention programs: the PROSPER delivery system. J. Adolesc. Health 2012, 50:256-263.
12. Curie C. Drug Prevention and Control. FDCH Congressional Testimony 2005, FDCH, Washington, DC.
13. Dunworth T., Mills G., Cordner G., Greene J. National Evaluation of Weed and Seed Cross-site Analysis 1999, U.S. Department of Justice, Washington, DC.
14. Epidemic: responding to America's prescription drug abuse crisis White House Office of National Drug Control Policy 2011, Office of National Drug Control Policy.
15. FDA Agenda:Drug Safety and Risk Management Advisory Committee (DSaRM) (Agenda) 2013, (Silver Spring, MD).
16. Fischer B., Gittens J., Rehm J. Characterizing the "awakening elephant" of prescription opioid misuse in North America: epidemiology, harms, interventions. Contemp. Drug Probl. 2008, 35:397.
17. Gourlay D.L., Heit H.A. Universal precautions revisited: managing the inherited pain patient. Pain Med. 2009, 10:S115-S123.
18. Greenberg M.T., Domitrovich C., Bumbarger B. The prevention of mental disorders in school-aged children: current state of the field. Prev. Treat. 2001, 4.
19. Guyll M., Spoth R., Crowley D.M. Economic analysis of methamphetamine prevention effects and employer costs. J. Stud. Alcohol Drugs 2011, 72:577-585.
20. Hansen R.N., Oster G., Edelsberg J., Woody G.E., Sullivan S.D. Economic costs of nonmedical use of prescription opioids. Clin. J. Pain 2011, 27:194-202.
21. Havens J.R. Nonmedical prescription drug use in a nationally representative sample of adolescents. Arch. Pediatr. Adolesc. Med. 2011, 165:250.
22. Hawkins J. Communities that Care: Action for Drug Abuse Prevention 1992, Jossey-Bass, San Francisco.
23. Hawkins J.D. Results of a type 2 translational research trial to prevent adolescent drug use and delinquency: a test of communities that care. Arch. Pediatr. Adolesc. Med. 2009, 163:789.
24. Hawkins J.D., Catalano R.F., Miller J.Y. Risk and protective factors for alcohol and other drug problems in adolescence and early adulthood: implications for substance abuse prevention. Psychol. Bull. 1992, 112:64-105.
25. Hernandez S.H., Nelson L.S. Prescription drug abuse: insight into the epidemic. Clin. Pharmacol. Ther. 2010, 88:307-317.
26. Johnston L., O'Malley P., Bachman J., Schulenberg J. Monitoring the Future: National Survey Results on Drug Use, 1975-2008. NIH Publication No. 09-7402 2010, vol. I. (WWW Document]. URL http://eric.ed.gov/ERICWebPortal/search/detailmini.jsp?_nfpb=true&_&ERICExtSearch_SearchValue_0=ED508295&ERICExtSearch_SearchType_0=no&accno=ED508295 (accessed 5.20.12)).
27. Katz N.P., Adams E.H., Chilcoat H., et al. Challenges in the development of prescription opioid abuse-deterrent formulations. Clin. J. Pain 2007, 23:648-660.
28. Koh H.K., Sebelius K.G. Promoting prevention through the affordable care act. N. Engl. J. Med. 2010, 363:1296-1299.
29. Kumpfer K.L., Alvarado R. Family-strengthening approaches for the prevention of youth problem behaviors. Am. Psychol. 2003, 58:457-465.
30. Littell R. SAS for Mixed Models 2006, SAS Institute, Cary N.C. 2nd ed.
31. Manchikanti L., Singh A. Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician 2008, 11:S63-S88.
32. Maxwell J.C. The prescription drug epidemic in the United States: a perfect storm. Drug Alcohol Rev. 2011, 30:264-270.
33. McCabe S.E. Motives for nonmedical use of prescription opioids among high school seniors in the united states: self-treatment and beyond. Arch. Pediatr. Adolesc. Med. 2009, 163:739.
34. McCabe S.E. Medical misuse of controlled medications among adolescents. Arch. Pediatr. Adolesc. Med. 2011, 165:729.
35. McCabe S.E. Medical and nonmedical use of prescription opioids among high school seniors in the United States. Arch. Pediatr. Adolesc. Med. 2012, 166:797.
36. McLellan A.T. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 2000, 284:1689-1695.
37. Meier E.A. Extramedical use of prescription pain relievers by youth aged 12 to 21years in the United States. Arch. Pediatr. Adolesc. Med. 2012, 166:803.
38. O'Connell M.E., Boat T.F., Warner K.E. Preventing Mental, Emotional, and Behavioral Disorders Among Young People: Progress and Possibilities 2009, National Academies Press, Washington, D.C.
39. Polsky D., Glick H.A., Yang J., Subramaniam G.A., Poole S.A., Woody G.E. Cost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: data from a randomized trial: Buprenorphine cost-effectiveness in youth. Addiction 2010, 105:1616-1624.
40. Robins J.M., Hernán M.A., Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000, 11:550-560.
41. Rosenbaum P.R., Rubin D.B. The central role of the propensity score in observational studies for causal effects. Biometrika 1983, 70:41-55.
42. Russell L.B., Gold M.R., Siegel J.E., Daniels N., Weinstein M.C. The role of cost-effectiveness analysis in health and medicine. JAMA 1996, 276:1172-1177.
43. Samet J.H. Benefits of linking primary medical care and substance abuse services: patient, provider, and societal perspectives. Arch. Intern. Med. 2001, 161:85-91.
44. SAMHSA National Admissions to Substance Abuse Treatment Services; 2005-2007 2009, Substance Abuse and Mental Health Services Administration, Office of Applied Studies, Rockville, MD.
45. Schackman B., Leff J., Polsky D., Moore B., Fiellin D. Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care. J. Gen. Intern. Med. 2012, 27:669-676.
46. Spoth R.L. Long-term effects of universal preventive interventions on methamphetamine use among adolescents. Arch. Pediatr. Adolesc. Med. 2006, 160:876-882.
47. Spoth R. Universal Prevention for Prescription Drug Misuse: Challenges, Findings, Opportunities for Impact 2011.
48. Spoth R. Developing a national evidence-based intervention delivery system based on the PROSPER Partnership model 2011.
49. Spoth R., Greenberg M., Bierman K., Redmond C. PROSPER community-university partnership model for public education systems: capacity-building for evidence-based, competence-building prevention. Prev. Sci. 2004, 5:31-39.
50. Spoth R., Guyll M., Lillehoj C.J., Redmond C., Greenberg M. Prosper study of evidence-based intervention implementation quality by community-university partnerships. J. Community Psychol. 2007, 35:981-999.
51. Spoth R., Redmond C., Shin C., Greenberg M., Clair S., Feinberg M. Substance-use outcomes at 18months past baseline. Am. J. Prev. Med. 2007, 32:395-402.
52. Spoth R., Trudeau L., Shin C., Redmond C. Long-term effects of universal preventive interventions on prescription drug misuse. Addiction 2008, 103:1160-1168.
53. Spoth R.L., Randall G.K., Trudeau L., Shin C., Redmond C. Substance use outcomes 5 1/2years past baseline for partnership-based, family-school preventive interventions. Drug Alcohol Depend. 2008, 96:57-68.
54. Spoth R., Guyll M., Redmond C., Greenberg M., Feinberg M. Six-year sustainability of evidence-based intervention implementation quality by community-university partnerships: the PROSPER study. Am. J. Community Psychol. 2011, 48:412-425.
55. Spoth R., Trudeau L., Shin C., Ralston E., Redmond C., Greenberg M., Feinberg M. Longitudinal Effects of Universal Preventive Intervention on Prescription Drug Misuse: Three Randomized Controlled Trials With Late Adolescents and Young Adults. American journal of public health 2013, 103(4):665-672.
56. Volkow N.D. Curtailing diversion and abuse of opioid analgesics without jeopardizing pain treatment. JAMA 2011, 305:1346.
57. Wandersman A. Getting to outcomes: a results-based approach to accountability. Eval. Program Plann. 2000, 23:389-395.